Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of three abstracts for presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentations include:
1. An oral presentation on the phase 2 LuminICE-203 study of acimtamig in combination with AlloNK® (AB-101) for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30.
2. Two poster presentations on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC): one focusing on EGFR-expressing NSCLC without driver mutations, and another on NSCLC with EGFR kinase domain mutations. Both posters will be presented on June 2.
The full abstracts will be published online on May 22, 2025.
Affimed N.V. (Nasdaq: AFMD) ha annunciato l'accettazione di tre abstract per la presentazione al Meeting Annuale 2025 della American Society for Clinical Oncology (ASCO) a Chicago. Le presentazioni includono:
1. Una presentazione orale sullo studio di fase 2 LuminICE-203 su acimtamig in combinazione con AlloNK® (AB-101) per il linfoma di Hodgkin classico recidivante o refrattario, prevista per il 30 maggio.
2. Due presentazioni poster su AFM24 in combinazione con atezolizumab per il carcinoma polmonare non a piccole cellule (NSCLC): una focalizzata su NSCLC con espressione di EGFR senza mutazioni driver, e l'altra su NSCLC con mutazioni nel dominio chinasi di EGFR. Entrambi i poster saranno presentati il 2 giugno.
Gli abstract completi saranno pubblicati online il 22 maggio 2025.
Affimed N.V. (Nasdaq: AFMD) ha anunciado la aceptación de tres resúmenes para su presentación en la Reunión Anual 2025 de la American Society for Clinical Oncology (ASCO) en Chicago. Las presentaciones incluyen:
1. Una presentación oral sobre el estudio de fase 2 LuminICE-203 de acimtamig en combinación con AlloNK® (AB-101) para linfoma de Hodgkin clásico en recaída o refractario, programada para el 30 de mayo.
2. Dos presentaciones en formato póster sobre AFM24 en combinación con atezolizumab para cáncer de pulmón no microcítico (NSCLC): una centrada en NSCLC con expresión de EGFR sin mutaciones driver, y otra en NSCLC con mutaciones en el dominio quinasa de EGFR. Ambos pósters se presentarán el 2 de junio.
Los resúmenes completos se publicarán en línea el 22 de mayo de 2025.
Affimed N.V. (나스닥: AFMD)가 시카고에서 열리는 2025 미국임상종양학회(ASCO) 연례회의에서 발표할 세 개의 초록이 승인되었다고 발표했습니다. 발표 내용은 다음과 같습니다:
1. 재발성 또는 불응성 고전적 호지킨 림프종에 대한 AlloNK®(AB-101)과 병용한 acimtamig의 2상 LuminICE-203 연구에 관한 구두 발표가 5월 30일 예정되어 있습니다.
2. 비소세포폐암(NSCLC)을 대상으로 한 atezolizumab과 병용한 AFM24에 관한 두 개의 포스터 발표: 하나는 드라이버 변이가 없는 EGFR 발현 NSCLC에 초점을 맞추었고, 다른 하나는 EGFR 키나제 도메인 변이가 있는 NSCLC에 관한 것입니다. 두 포스터 모두 6월 2일에 발표됩니다.
전체 초록은 2025년 5월 22일 온라인으로 공개될 예정입니다.
Affimed N.V. (Nasdaq : AFMD) a annoncé l'acceptation de trois résumés pour présentation lors du Congrès annuel 2025 de l'American Society for Clinical Oncology (ASCO) à Chicago. Les présentations comprennent :
1. Une présentation orale sur l'étude de phase 2 LuminICE-203 portant sur acimtamig en combinaison avec AlloNK® (AB-101) pour le lymphome classique de Hodgkin en rechute ou réfractaire, prévue le 30 mai.
2. Deux présentations sous forme de posters sur AFM24 en combinaison avec atezolizumab pour le cancer du poumon non à petites cellules (NSCLC) : une portant sur le NSCLC exprimant l'EGFR sans mutations driver, et une autre sur le NSCLC avec mutations dans le domaine kinase de l'EGFR. Les deux posters seront présentés le 2 juin.
Les résumés complets seront publiés en ligne le 22 mai 2025.
Affimed N.V. (Nasdaq: AFMD) hat die Annahme von drei Abstracts für die Präsentation auf dem Jahrestreffen 2025 der American Society for Clinical Oncology (ASCO) in Chicago bekanntgegeben. Die Präsentationen umfassen:
1. Eine mündliche Präsentation zur Phase-2-Studie LuminICE-203 mit Acimtamig in Kombination mit AlloNK® (AB-101) bei rezidivierendem oder refraktärem klassischem Hodgkin-Lymphom, geplant für den 30. Mai.
2. Zwei Posterpräsentationen zu AFM24 in Kombination mit Atezolizumab bei nicht-kleinzelligem Lungenkarzinom (NSCLC): eine mit Fokus auf EGFR-exprimierende NSCLC ohne Treibermutationen und eine weitere zu NSCLC mit EGFR-Kinasedomänen-Mutationen. Beide Poster werden am 2. Juni präsentiert.
Die vollständigen Abstracts werden am 22. Mai 2025 online veröffentlicht.
- Acceptance of oral presentation for phase 2 LuminICE-203 study indicates significant clinical progress
- Multiple presentation formats (oral and posters) demonstrate broad clinical development program
- Diverse cancer indications (lymphoma and NSCLC) show pipeline expansion
- None.
MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE®) acimtamig in combination with AlloNK® (AB-101) has been accepted for an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025 in Chicago, Illinois. In addition, two abstracts on AFM24 in combination with atezolizumab in non-small cell lung cancer (NSCLC) have been accepted as poster presentations.
Details of the acimtamig oral presentation and AFM24 poster presentations are as follows:
| Abstract Title & Number | Date & Time | Session Type & Title |
| Results from the completed dose-finding part of a phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203) Abstract Number for Publication: 7008 | May 30, 2025 2:45 PM-5:45 PM CDT | Oral Abstract Session – Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
| Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR-expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study Abstract Number for Publication: 2609 | June 2, 2025 1:30 PM-4:30 PM CDT | Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 256 |
| Combination of bispecific innate cell engager (ICE) AFM24 with atezolizumab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR kinase domain mutations (EGFRmut): Initial results from a phase 2a study Abstract Number for Publication: 2610 | June 2, 2025 1:30 PM-4:30 PM CDT | Poster Session – Developmental Therapeutics—Immunotherapy Poster Board: 257 |
The full abstracts will be published online on May 22, 2025.
More details about the programs for the 2025 ASCO Annual Meeting are available online at Attend | ASCO Annual Meeting.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Investor Relations Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102
Media Contact
Mary Beth Sandin
Vice President, Marketing and Communications
E-Mail: m.sandin@affimed.com
FAQ
What clinical trial results will Affimed (AFMD) present at ASCO 2025?
When will Affimed's (AFMD) ASCO 2025 abstracts be published?
What are the different NSCLC patient populations in Affimed's (AFMD) AFM24 studies?
What is the format and timing of Affimed's (AFMD) presentations at ASCO 2025?
